2. Signaling Pathways
  3. Immunology/Inflammation
  4. IFNAR

IFNAR

Interferon-α/β receptor; Interferon-alpha/beta receptor

IFNAR

Related Products

PDF 0.27 MB

The interferon-α/β receptor (IFNAR) is composed of two subunits, IFNAR1 and IFNAR2, encoding transmembrane polypeptides. Type-I IFNs, interferon α (IFN-α) and interferon β (IFN-β), act through a shared receptor complex, IFNAR. Binding of type-I IFN to IFNAR1 will robustly activate Janus activated kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Aberrant activation of the type-I IFN response results in a spectrum of disorders called interferonopathies.

Type-I IFN response occurs when IFN-α/β binds to their receptor complex, IFNAR. The ligand-receptor complex is phosphorylated, presumably by pre-associated Janus activated kinases (JAKs) namely tyrosine kinase 2 (TYK2) on IFNAR1 and JAK1 on IFNAR2. The phosphorylated receptors are docking sites for signal transducers and activators of transcription (STAT) factors that dimerise and translocate to the nucleus. STATs 1, 2, 3, 4, and 5 are activated by type-I IFNs in many cell types. Other kinases (e.g., mitogen-activated protein kinases) and transcription factors (e.g., nuclear factor-κB) can also be activated in response to type-I IFNs. Multiple pathways and IFN-regulated genes are activated by IFNs, many of which remain unknown.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P11356A
    KRAS G12V Peptide TFA
    		Activator
    KRAS G12V Peptide TFA is the trifluoroacetate salt of KRAS G12V Peptide (HY-P11355). KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors.
    KRAS G12V Peptide TFA
  • HY-160222
    HSV-60mer sodium
    		Inducer 98.11%
    HSV-60mer sodium is a 60 bp double-stranded DNA oligonucleotide derived from the HSV-1 genome, and also an IFNβ inducer. HSV-60mer sodium colocalizes with endogenous cytoplasmic IFI16 in immune cells. HSV-60mer sodium activates the transcription factors IRF3 and NF-κB, induces the production of proinflammatory cytokines, and inhibits HSV-1 replication in immune cells. HSV-60mer sodium can be used in studies related to herpes simplex virus type 1 infection.
    HSV-60mer sodium
  • HY-181526
    Sim-9
    		Inhibitor
    Sim-9 is a covalent allosteric inhibitor of interferon regulatory factor 3 (IRF3). Sim-9 binds covalently to the Cys222 residue of IRF3, induces its conformational change, blocks its interactions with TRIF, MAVS and STING, and inhibits IRF3 homodimerization and type I interferon response. Sim-9 exhibits significant anti-inflammatory, organ-protective and survival benefits in mouse models of sepsis and acute pancreatitis. Sim-9 can be used for research related to inflammatory diseases.
    Sim-9
  • HY-163035
    EM-163
    		Inhibitor
    EM-163 is a summative BB-Loop analog. EM-163 can alleviate inflammation and prevent death from toxic shock by targeting the TIR domain of MyD88. EM-163 can be used in the study of SEB poisoning (SEB: Staphylococcal enterotoxin B).
    EM-163
  • HY-12836
    IFN alpha-IFNAR-IN-1
    		Inhibitor 98.43%
    IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC50=2-8 μM).
    IFN alpha-IFNAR-IN-1
  • HY-123630R
    Allura Red AC (Standard)
    		Activator
    Allura Red AC (Standard) is an analytical standard of Allura Red AC. This product is intended for research and analytical applications. Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety.
    Allura Red AC (Standard)
  • HY-177632B
    Frenlosirsen scrambled control
    		Control
    Frenlosirsen scrambled control is a scrambled control antisense oligonucleotide of Frenlosirsen (HY-177632) with a scrambled sequence in the target binding region.
    Frenlosirsen scrambled control
  • HY-152169
    BIHC
    		Inhibitor ≥98.0%
    BIHC is a TNF blocker with anti-inflammatory activity. BIHC can significantly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and exhibits potent cytotoxicity against the HepG2 cell line, capable of inducing cell apoptosis , while demonstrating relatively low toxicity towards normal hepatocytes. Additionally, BIHC can be used for research on inflammatory bowel disease (IBD).
    BIHC
  • HY-P992201
    Anti-CD160 Antibody (MAT 302)
    		Activator
    Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma.
    Anti-CD160 Antibody (MAT 302)
  • HY-108839
    Peginterferon alfa-2a
    		Agonist
    Peginterferon alfa-2a is a PEG-modified interferon (IFN) alpha-2a. Peginterferon alfa-2a can be used for research of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection.
    Peginterferon alfa-2a
  • HY-117287A
    Deucravacitinib (hydrochloride)
    		Inhibitor
    Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
    Deucravacitinib (hydrochloride)
  • HY-183866
    MPD-1
    		Inducer
    MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 releases Doxorubicin (HY-15142) via radiation-activated caspase-3 cleavage, triggering a cytotoxic amplification cascade at the tumor site. MPD-1 enhances CD8+ T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer.
    MPD-1
  • HY-P11356
    KRAS G12V Peptide
    		Activator
    KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors.
    KRAS G12V Peptide
  • HY-182693
    CPL302-253
    		Inhibitor
    CPL302-253 is a PI3Kδ inhibitor with an IC50 of 12.20 nM and a human Kd of 0.85 nM. CPL302-253 functionally regulates PI3Kδ activity, blocks the production of IFNγ, IL-33 and ROS in immune cells, and affects immune function. CPL302-253 blocks the progression of asthma-inducing inflammatory responses in a mouse model of asthma. CPL302-253 can be used for research related to asthma.
    CPL302-253
  • HY-P991426
    MB-314
    		Activator
    MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research.
    MB-314
  • HY-16362
    Omtriptolide sodium
    		Inhibitor
    Omtriptolide sodium (PG490-88Na) is a derivative of Triptolide (HY-32735). Omtriptolide sodium exhibits significant immunosuppressive, anti-fibrotic and anti-inflammatory properties. The mechanism of action of Omtriptolide sodium is diverse, including inhibiting T cell activation and proliferation, inducing T cell apoptosis (apoptosis), blocking fibroblast maturation/proliferation, inhibiting TGF-β mRNA expression, and suppressing pro-inflammatory cytokines (such as IL-2, IFN-γ, TNF-α) by blocking transcription factors such as NF-κB. Omtriptolide sodium can be used for research on obstructive airway diseases, pulmonary fibrosis and graft-versus-host disease.
    Omtriptolide sodium
  • HY-P11123
    MSP-1 (20-39)
    		Activator
    MSP-1 (20-39) is a peptide segment that can induce the production of IFN-γ. MSP-1 (20-39) has the potential to serve as a malaria vaccine. MSP-1 (20-39) can be used for research on malaria or immunology.
    MSP-1 (20-39)
  • HY-P991475
    MG-1131
    		Activator
    MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    MG-1131
  • HY-175236
    SF-9-2
    		Agonist
    SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research.
    SF-9-2
  • HY-163704
    KRN7000 analog 1
    		Agonist
    KRN7000 analog 1 exhibits good Th1-biased immune response through induction of interferon-γ (IFN-γ) and reduction of interleukin-4 (IL-4). KRN7000 analog 1 is potential as an antitumor agent and vaccine adjuvant.
    KRN7000 analog 1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity